在药物涂层气球治疗中整合一种抗收缩化合物
Dima BaniHani1, John F Eberth2, Francis G Spinale1,3,4
1Department of Biomedical Engineering, College of Engineering and Computing, University of South Carolina, Columbia, SC, 29208, USA.
Cardiovascular engineering and technology
|July 27, 2025
概括
本研究探讨将瓦尔萨坦 (VAL) 添加到药物涂层气球 (DCB) 中,通过放松血管光滑肌细胞 (vSMCs) 来预防外周动脉疾病 (PAD) 静脉缩. 帕克利塔克塞尔 (PTX) 和VAL的同时递送显示了改善DCB治疗结果的希望.
科学领域:
- 血管生物学和再生医学
- 药物输送系统和纳米技术
- 心血管药理学心血管药理学
背景情况:
- 药物涂层气球 (DCB) 疗法对外周动脉疾病 (PAD) 有效,但由于内侧血管改造导致的晚期光量损失而受到限制.
- 内部重塑与血管光滑肌细胞 (vSMC) 度升高有关,通常由PAD并发症 (如高血压和内皮功能障碍) 加剧.
研究的目的:
- 通过减弱vSMC声调来提高DCB功效的新策略.
- 探索帕克利塔克塞尔 (PTX) 和瓦尔萨坦 (VAL) 的同时提供,以改善光线通透性并减少治疗后的重塑.
主要方法:
- 考虑了PTX和瓦尔萨坦 (VAL) 的局部同时递送,这是一种已知的诱导vSMC放松的抗高血压药物.
- 使用尿素作为辅助剂,用于形成能够同时提供PTX和VAL的气球涂层.
- 研究了新型DCB涂层的高效药物输送的结构功能关系.
主要成果:
- 量化了VAL在诱导动脉组织中局部vSMC放松方面的疗效.
- 以尿素为基础的气球涂层证明了同时提供PTX和VAL的可行性.
- 阐明了关键的结构-功能关系,以优化药物输送.
结论:
- 瓦尔萨坦 (VAL) 具有将其纳入DCB配方的潜力,以减轻治疗后动脉重塑的风险.
- 需要进行进一步的体外实验,以确定通过DCBs联合输送PTX和VAL的安全性和有效性.
相关概念视频
01:27Peripheral Artery Disease III: Interprofessional Care
29
Peripheral Artery Disease (PAD) is characterized by narrowed arteries that diminish blood flow to the extremities. Effective management of PAD requires an interprofessional approach involving various healthcare professionals. The critical aspects of interprofessional care for PAD patients focus on risk factor modification, drug therapy, exercise therapy, nutrition therapy, critical limb ischemia care, and interventional radiology and surgical procedures.The primary treatment goal for PAD...
29
01:20Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors
646
Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
646
01:23Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists
254
Prostacyclin receptor agonists are a class of therapeutic agents integral to managing pulmonary arterial hypertension (PAH). These drugs operate by mimicking the action of prostaglandin I2, or PGI2, a naturally occurring compound in the body.
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
254
01:27Coronary Artery Disease V: Interprofessional Care
33
Interprofessional care for coronary artery disease includes pharmacological therapy and revascularization procedures.Pharmacological therapy for Coronary Artery Disease (CAD) aims to manage symptoms, prevent complications, and improve patient outcomes through various classes of medications:Antiplatelet Agents:Aspirin and Clopidogrel: These medications inhibit platelet aggregation, preventing blood clots, which is crucial for avoiding heart attacks and strokes. Doctors often prescribe these...
33
01:25Antianginal Drugs: Calcium Channel Blockers and Ranolazine
684
Angina pectoris, a primary symptom of ischemic heart disease, requires careful pharmacological interventions. In this context, calcium channel blockers (CCBs) and ranolazine have emerged as crucial pharmacotherapeutic agents, providing deep insights into the complexities of angina management.
CCBs, a diverse class that includes dihydropyridines (nifedipine) and diphenylalkylamines (verapamil and diltiazem), exert their effect by blocking calcium channels in cardiac and smooth muscle cells. This...
CCBs, a diverse class that includes dihydropyridines (nifedipine) and diphenylalkylamines (verapamil and diltiazem), exert their effect by blocking calcium channels in cardiac and smooth muscle cells. This...
684
01:26Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
510
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
510